Equities analysts forecast that Humana Inc (NYSE:HUM) will post $15.90 billion in sales for the current quarter, Zacks Investment Research reports. Six analysts have provided estimates for Humana’s earnings, with estimates ranging from $15.87 billion to $15.97 billion. Humana posted sales of $14.26 billion in the same quarter last year, which would indicate a positive year over year growth rate of 11.5%. The business is scheduled to issue its next earnings results on Wednesday, August 7th.

According to Zacks, analysts expect that Humana will report full-year sales of $63.75 billion for the current year, with estimates ranging from $63.66 billion to $63.85 billion. For the next year, analysts forecast that the company will report sales of $69.35 billion, with estimates ranging from $68.36 billion to $70.57 billion. Zacks’ sales averages are an average based on a survey of sell-side research firms that follow Humana.

Humana (NYSE:HUM) last posted its quarterly earnings data on Wednesday, May 1st. The insurance provider reported $4.48 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $4.30 by $0.18. Humana had a net margin of 2.99% and a return on equity of 20.77%. The business had revenue of $16.11 billion during the quarter, compared to analyst estimates of $15.67 billion. During the same quarter last year, the firm posted $3.36 earnings per share. The business’s revenue for the quarter was up 12.8% compared to the same quarter last year.

A number of research analysts recently issued reports on HUM shares. Credit Suisse Group decreased their price target on shares of Humana from $352.00 to $315.00 and set an “outperform” rating for the company in a research note on Thursday, May 2nd. Citigroup decreased their price target on shares of Humana from $397.00 to $362.00 and set a “buy” rating for the company in a research note on Thursday, February 7th. Barclays decreased their price target on shares of Humana from $351.00 to $327.00 and set an “overweight” rating for the company in a research note on Wednesday, April 17th. Oppenheimer decreased their price target on shares of Humana from $373.00 to $350.00 and set an “outperform” rating for the company in a research note on Thursday, May 2nd. Finally, ValuEngine downgraded shares of Humana from a “hold” rating to a “sell” rating in a research note on Thursday, April 11th. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating and fourteen have given a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $337.26.

Shares of NYSE HUM traded up $1.46 during midday trading on Monday, hitting $245.14. The company’s stock had a trading volume of 25,621 shares, compared to its average volume of 1,332,844. Humana has a 1 year low of $225.65 and a 1 year high of $355.88. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.65 and a current ratio of 1.65. The firm has a market cap of $31.83 billion, a price-to-earnings ratio of 16.83, a PEG ratio of 0.97 and a beta of 0.88.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 26th. Stockholders of record on Friday, June 28th will be given a dividend of $0.55 per share. The ex-dividend date is Thursday, June 27th. This represents a $2.20 annualized dividend and a dividend yield of 0.90%. Humana’s dividend payout ratio is presently 15.12%.

In other news, insider Roy A. Beveridge sold 8,278 shares of the business’s stock in a transaction that occurred on Tuesday, February 19th. The shares were sold at an average price of $307.16, for a total transaction of $2,542,670.48. Following the completion of the sale, the insider now owns 12,409 shares in the company, valued at approximately $3,811,548.44. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Christopher H. Hunter sold 15,586 shares of the business’s stock in a transaction that occurred on Monday, February 25th. The stock was sold at an average price of $305.24, for a total transaction of $4,757,470.64. Following the sale, the insider now owns 28,100 shares of the company’s stock, valued at approximately $8,577,244. The disclosure for this sale can be found here. 0.54% of the stock is currently owned by insiders.

Several large investors have recently modified their holdings of HUM. Nordea Investment Management AB increased its holdings in shares of Humana by 17.7% in the 3rd quarter. Nordea Investment Management AB now owns 22,339 shares of the insurance provider’s stock valued at $7,562,000 after acquiring an additional 3,359 shares during the period. Morgan Stanley increased its holdings in shares of Humana by 130.5% in the 3rd quarter. Morgan Stanley now owns 368,401 shares of the insurance provider’s stock valued at $124,712,000 after acquiring an additional 208,595 shares during the period. Vanguard Group Inc increased its holdings in shares of Humana by 1.4% in the 3rd quarter. Vanguard Group Inc now owns 10,104,225 shares of the insurance provider’s stock valued at $3,420,482,000 after acquiring an additional 140,864 shares during the period. Federated Investors Inc. PA increased its holdings in shares of Humana by 598.6% in the 3rd quarter. Federated Investors Inc. PA now owns 134,741 shares of the insurance provider’s stock valued at $45,612,000 after acquiring an additional 115,453 shares during the period. Finally, Cerebellum GP LLC acquired a new position in shares of Humana in the 4th quarter valued at $153,000. Institutional investors and hedge funds own 94.72% of the company’s stock.

About Humana

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company offers medical and supplemental benefit plans to individuals. It also has contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

Featured Article: What is the return on assets (ROA) ratio?

Get a free copy of the Zacks research report on Humana (HUM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.